We understand that Kakan Pharm of Japan has, at very long, long, long last received approval from Japan's equivalent of the FDA to begin selling Fiblast, a Scios developed product licensed to Kakan for Asia only, for dermal wounds, the first of what could be multiple, or at least some, licensed Fiblast uses worldwide, and for possibly other indications. This happened only recently. No annoucement yet from Scios. At last report, Scios IR was waiting for paper confirmation before issuing release. Anyone have anything new on this?